Compare QTWO & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QTWO | GKOS |
|---|---|---|
| Founded | 2004 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 6.9B |
| IPO Year | 2014 | 2015 |
| Metric | QTWO | GKOS |
|---|---|---|
| Price | $50.50 | $120.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 14 |
| Target Price | $86.25 | ★ $133.07 |
| AVG Volume (30 Days) | ★ 1.3M | 728.9K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 225.00 | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | $193,978,000.00 | ★ $507,442,000.00 |
| Revenue This Year | $12.48 | $23.29 |
| Revenue Next Year | $10.16 | $27.74 |
| P/E Ratio | $60.00 | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $46.16 | $73.16 |
| 52 Week High | $95.10 | $130.23 |
| Indicator | QTWO | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 35.68 | 56.24 |
| Support Level | N/A | $78.93 |
| Resistance Level | $75.62 | $130.23 |
| Average True Range (ATR) | 2.58 | 5.06 |
| MACD | 0.08 | 0.67 |
| Stochastic Oscillator | 32.82 | 88.63 |
Q2 Holdings Inc. is a provider of cloud-based virtual banking solutions for regional financial institutions to deliver mobile banking services to retail and commercial end-users who wish to bank anywhere and anytime. Its solutions operate on an integrated tablet-first platform which provides financial institutions a comprehensive view of account holder activity and meets the regulatory and security requirements applicable to the industry. The firm generates revenue from subscription-based arrangements for software offerings. A large majority of the firm's revenue is generated in the United States.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.